Moderna (MRNA) Stock Is Trading Lower Friday: What's Going On?
1. Moderna shares declined 3.75% following Thursday's spike driven by acquisition rumors. 2. The company halted its cytomegalovirus vaccine trial due to unmet efficacy benchmarks. 3. Analysts cut price targets significantly, indicating bearish sentiment on MRNA. 4. Upcoming earnings report estimates indicate quarterly losses of $2.17 per share. 5. The stock shows short-term momentum but negative long-term trends, affecting investor outlook.